- DEMENTIA RESEARCHER - https://www.dementiaresearcher.nihr.ac.uk -

Fits and Starts: Trial Results from the CTAD Conference

As in years past, trial results offered up a mixed bag of goods and duds at the Clinical Trials on Alzheimer’s Disease Conference, held October 24–27 in Barcelona, Spain. In the first Phase 3 AD trial ever conducted in China, a seaweed oligosaccharide was claimed to have halted or even reversed the slide into dementia of people with mild to moderate Alzheimer’s. In a more familiar story, another offbeat approach—a plasma exchange therapy—was reported to slow decline in people with moderate, but not mild, AD. Not so for the fyn kinase inhibitor saracatinib [1], which hit the end of the road. New Aβ vaccines advanced, and the first clinical trial of an antiviral drug potentially offers a new angle on AD. Finally, the neurosteroid allopregnanolone  [2]inched ahead, though estrogen receptor-modulating PhytoSERMs did not.

To read the rest of this blog and the second part visit the Alz Forum Website: https://www.alzforum.org/news/conference-coverage/fits-and-starts-trial-results-ctad-conference [3]